BRPI0515443A - combination of polychitosamine and hmg-coa reductase inhibitor for hyperlipidemia - Google Patents

combination of polychitosamine and hmg-coa reductase inhibitor for hyperlipidemia

Info

Publication number
BRPI0515443A
BRPI0515443A BRPI0515443-0A BRPI0515443A BRPI0515443A BR PI0515443 A BRPI0515443 A BR PI0515443A BR PI0515443 A BRPI0515443 A BR PI0515443A BR PI0515443 A BRPI0515443 A BR PI0515443A
Authority
BR
Brazil
Prior art keywords
frequency
channel
digital
audio
stereo
Prior art date
Application number
BRPI0515443-0A
Other languages
Portuguese (pt)
Inventor
Andre Aube
Jean-Guy Lehoux
Ryszard Brzezinski
Gilles Dupuis
Original Assignee
Dnp Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnp Canada Inc filed Critical Dnp Canada Inc
Publication of BRPI0515443A publication Critical patent/BRPI0515443A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Stereo-Broadcasting Methods (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"CODIFICAçãO DIGITAL DIRETA E MODULAçãO DE RáDIO FREQüêNCIA PARA TRANSMITIR APLICAçãO DE TELEVISãO". Um codificador de áudio digital, condicionador de vídeo digital, e um modulador digital são descritos para produzir um sinal de transmissão de televisão em uma faixa de freqüência de canal desejada. Sinais de canal de áudio esquerdo e direito são digitalizados e codificados de acordo com um padrão estéreo e então combinados para formar um sinal de áudio estéreo. Um segundo canal de programação de áudio pode ser incluído. Uma entrada de vídeo pode ser digitalizada e condicionada para formar um canal de vídeo digital. O sinal de áudio estéreo pode ser colocado diretamente em uma frequência de canal desejada por modulação de frequência sem a necessidade de usar uma frequência intermediária. O canal de vídeo digital pode ser colocado em uma frequência desejada por modulação de amplitude. Os canais de áudio e digitais podem ser digitalmente combinados para criar um sinal de transmissão de televisão em uma frequência desejada de acordo com um padrão desejado."DIRECT DIGITAL CODING AND RADIO MODULATION FREQUENCY TO TRANSMIT TELEVISION APPLICATION". A digital audio encoder, digital video conditioner, and digital modulator are described to produce a television broadcast signal over a desired channel frequency range. Left and right audio channel signals are digitized and encoded to a stereo standard and then combined to form a stereo audio signal. A second audio programming channel may be included. A video input can be digitized and conditioned to form a digital video channel. The stereo audio signal can be placed directly at a desired channel frequency by frequency modulation without the need to use an intermediate frequency. The digital video channel can be placed at a desired frequency by amplitude modulation. Audio and digital channels can be digitally combined to create a television broadcast signal at a desired frequency according to a desired standard.

BRPI0515443-0A 2004-09-15 2005-09-14 combination of polychitosamine and hmg-coa reductase inhibitor for hyperlipidemia BRPI0515443A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60983004P 2004-09-15 2004-09-15
PCT/CA2005/001406 WO2006029524A1 (en) 2004-09-15 2005-09-14 Combination of polychitosamine and hmg-coa reductase inhibitor for hyperlipidemia

Publications (1)

Publication Number Publication Date
BRPI0515443A true BRPI0515443A (en) 2008-07-29

Family

ID=36059676

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515443-0A BRPI0515443A (en) 2004-09-15 2005-09-14 combination of polychitosamine and hmg-coa reductase inhibitor for hyperlipidemia

Country Status (8)

Country Link
US (5) US20060058261A1 (en)
EP (1) EP1812019A4 (en)
JP (1) JP2008513379A (en)
CN (1) CN101052405A (en)
AU (1) AU2005284565A1 (en)
BR (1) BRPI0515443A (en)
CA (1) CA2580460A1 (en)
WO (1) WO2006029524A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20080182819A1 (en) * 2007-01-29 2008-07-31 Act Iii Licensing, Llc Chitosan compositions and methods for using chitosan compositions in the treatment of health disorders
JP5795304B2 (en) 2009-03-18 2015-10-14 レスバーロジックス コーポレイション New anti-inflammatory agent
JP5791116B2 (en) * 2009-04-08 2015-10-07 ナンヤン ポリテクニックＮａｎｙａｎｇ Ｐｏｌｙｔｅｃｈｎｉｃ Plant extracts containing statins and their preparation techniques and uses
CA2869821C (en) 2011-06-13 2018-06-19 Rival, Societe En Commandite N,n,n-trialkylaminopolymers, methods of their preparation and uses thereof
WO2020121074A1 (en) * 2018-09-26 2020-06-18 Tq-Systems Gmbh Method and device for dynamically controlling a range of an electrically-assisted bicycle, electrically-assisted bicycle
IT201900021291A1 (en) * 2019-11-15 2021-05-15 Biomedica Pharma Gmbh CHITOSAN AND MEDICAL PRODUCT FOR USE IN A METHOD OF PREVENTION OR TREATMENT OF A CARDIOVASCULAR DISEASE

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903140A (en) * 1970-09-08 1975-09-02 Alza Corp Diazadodecane prostaglandin compounds
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (en) * 1980-06-06 1986-07-28 Sankyo Co METHOD FOR PREPARING ML-236B CARBOXYLIC ACID DERIVATIVES
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
CA2146549C (en) * 1992-12-01 2005-01-04 Karl F. Roenigk Durable antimicrobial agents
FI107432B (en) * 1997-02-06 2001-08-15 Novasso Oy Use of microcrystalline chitosan
FI982291A (en) * 1998-10-23 2000-04-24 Novasso Oy An agent for lowering cholesterol and lipids
US20020016307A1 (en) * 1999-10-27 2002-02-07 Mullins John Jason Gentry Pharmaceutical composition with both a lipase inhibitor and a lipophilic polysaccharide and an improved method for treating adiposity
US6777552B2 (en) * 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
US6933291B2 (en) * 2000-12-01 2005-08-23 N.V. Nutricia Cholesterol lowering supplement
GB0302738D0 (en) * 2003-02-06 2003-03-12 Advanced Biopolymers As Composition

Also Published As

Publication number Publication date
US20090197830A1 (en) 2009-08-06
US20060058261A1 (en) 2006-03-16
US20130244973A1 (en) 2013-09-19
EP1812019A4 (en) 2007-12-26
EP1812019A1 (en) 2007-08-01
WO2006029524A1 (en) 2006-03-23
JP2008513379A (en) 2008-05-01
AU2005284565A1 (en) 2006-03-23
US20110028429A1 (en) 2011-02-03
US20120258932A1 (en) 2012-10-11
CA2580460A1 (en) 2006-03-23
CN101052405A (en) 2007-10-10

Similar Documents

Publication Publication Date Title
BRPI0515443A (en) combination of polychitosamine and hmg-coa reductase inhibitor for hyperlipidemia
TW200623878A (en) Direct digital encoding and radio frequency modulation for broadcast television application
WO2006084916A3 (en) Parametric joint-coding of audio sources
AU2003216686A1 (en) Parametric multi-channel audio representation
HK1099879A1 (en) Transmission of signaling information for broadcast and multicast services
WO2008110003A8 (en) A universal television receiver
WO2009100246A3 (en) Systems, methods, and devices for scanning broadcasts
MX2009013560A (en) Digital broadcasting system and data processing method.
WO2006020376A3 (en) Method of transmitting audio and video signals overs radio and television channels
EP2005787A4 (en) Audio signal processing
AU2002322503A1 (en) Digital audio/video broadcast on cellular systems
WO2008157549A3 (en) Apparatus and methods of enhancing radio programming
EP1616424A4 (en) Wideband multi-channel quadrature amplitude modulation of cable television signals
AU2003298371A1 (en) Secure transmission of audio signals
GB0313658D0 (en) Secure transmission of audio signals
MX2007008932A (en) Bendable polyolefin films.
CN104410946A (en) Method and system for realizing multichannel output audio through wireless multi-equipment combination
DE69901546D1 (en) UNIVERSAL SIGNAL DISTRIBUTION SYSTEM
ECSP034457A (en) LOW COST VSB ENCODER AND FR MODULATOR TO SUPPLY A 6MHZ VSB SUBSTANTIAL SIGNAL TO A DIGITAL TELEVISION RECEIVER
GB0405404D0 (en) Receiver for down-conversion of dual band for digital multimedia broadcasting or digital audio broadcasting
AU2003299204A1 (en) Focal calcium channel modulation
WO2008057133A3 (en) Positional linking of analog two-way radios
GB0307448D0 (en) Modulated output of digital audio signals
RU2006144618A (en) METHOD FOR TRANSFER OF DIGITAL INFORMATION IN AUDIO BROADCASTING CHANNELS AND TELEPHONE CHANNELS
UA49416A (en) Method for transmitting sound programs with television signals

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.